PDSB - Bull Thesis
(Updated 4/6/2022)
BULL THESIS SUMMARY
PDSB overall corporate and summary
Immuno-oncology company with novel cancer vaccine technology
Initial efficacy results using HPV immunotherapy (PDS0101) on head & neck and other HPV cancers were impressive
Clinical partnerships with Merck, MD Anderson cancer Center and National Cancer Institute
Market cap of $170M (EV of ~$110M) is very attractive for a company with POC data in HPV cancers
Debt free and almost $70M (>2 yrs) in cash as of Q4 ‘21
FS/MV 4/6/22
(See below for full bull/bear analysis)
BULL THESIS
PDSB overall corporate and summary
Immuno-oncology company with novel cancer vaccine technology
Initial efficacy results using HPV immunotherapy (PDS0101) on head & neck and other HPV cancers were impressive
Clinical partnerships with Merck, MD Anderson cancer Center and National Cancer Institute
Market cap of $170M (EV of ~$110M) is very attractive for a company with POC data in HPV cancers
Debt free and almost $70M (>2 yrs) in cash as of Q4 ‘21
PDS0101 (Versamune based immunotherapies)
Novel cancer immunotherapy vaccine technology targeting HPV cancers
Binary/Mover data to be presented throughout first half of 2022
Patents protection thru mid 2030’s
Versamune based therapy has potential to generate the right type and quantity of CD8+ killer T cells, generate memory T cells and generate potency without systemic side effects
PDS0101 + M7824 and NHS-IL12 (Phase 2)
Stock jumped over 100% when presented at ASCO21 in June 2021
Tumor reduction in 83% of patients (advanced HPV16 positive CPI naive patients)
58% tumor reduction in HPV16 checkpoint inhibitor refractory patients
The first ⅚ patients responded compared to historical 15-20% ORR
Updated data coming at conference in 2022
PDS0101 + Keytruda (partnered with Merck) - VERSATILE-002 (Phase 2)
No dose limiting toxicities and OK safety (Sept 2021)
Preliminary ORR benchmarks were met (Feb 2022)
Will now progress to full enrollment
Achieved ORR in at least 4 of first 17 patients
In Keytruda monotherapy trials, ORR was 16% and complete response rate was 5% (33% of participants had HPV+ tumors and ORR irrespective of HPV status)
Prelim efficacy data expected at conference in 2022
Initiated additional investigator led trial in Feb 2022 and expect preliminary data in mid 2022
PDS0101 + Chemo-radiation (Phase 2)
Data expected in Q2 or early Q3 2022
Additional pipeline candidates entering clinical trials by end of year
PDS0102, PDS0103, PDS0104, PDS0202
PDS0102 targets TARP protein
Expect to start PDS0102 trial with prostate cancer indication
PDS0203 2nd gen COVID vaccine, partnership extended to May 2022 with Farmacore
Infectimune (second proprietary technology)
Proprietary T-cell immune activating platform technology designed to train the immune system to better protect against disease.
FS/MV 2/4/22 (updated 4/6/22)
See the bull/bear analysis in our BPIQ Pro Forum post here and the full bull/bear analysis w/ Amp view in our Amp Premium Forum post here. To become a subscriber Learn more here.